Many potential drug candidates fail to advance because of a lack of clinical activity at tolerated doses or because of unmanageable toxicities. Other limitations include a deficit of drug-like ...
Over the past two decades, numerous complex cancer therapies called antibody drug conjugates (ADCs) have been tested in clinical trials and approved for use in patients. Investigators recently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results